First Horizon Advisors, Inc. Alnylam Pharmaceuticals, Inc. Call Options Transaction History
First Horizon Advisors, Inc.
- $3.28 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
592Shares Held
104MCall Options Held
2.82MPut Options Held
1.75M-
Capital World Investors Los Angeles, CA12.8MShares$3.01 Billion0.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$2.83 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY9.03MShares$2.13 Billion0.03% of portfolio
-
Wellington Management Group LLP Boston, MA7.21MShares$1.7 Billion0.2% of portfolio
-
Baillie Gifford & CO6.62MShares$1.56 Billion0.78% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $29B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...